Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2023-04-27 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science - Résumé de la présentation dans la SLA à la réunion annuelle 2023 de l'AAN
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that AB Science is summarizing the presentation given on masitinib for ALS at the 2023 American Academy of Neurology (AAN) annual meeting. It details scientific results (survival analysis, functional assessments) presented at the conference and provides a link to the presentation PDF. Since the document itself is an announcement summarizing external presentation data and results, and it is not the full Annual Report (10-K), a comprehensive Interim Report (IR), or a formal Earnings Release (ER), it best fits the category of an Investor Presentation (IP) summary or, more broadly, a communication related to investor information presented at a scientific meeting. However, given the context of summarizing scientific data presented at a major conference, and the fact that the presentation itself is linked, it strongly aligns with the purpose of an Investor Presentation (IP) or a detailed scientific update often shared with investors. Since the text is a detailed summary of clinical data presented at a conference, 'Investor Presentation' (IP) is the most appropriate fit, as it conveys detailed strategic/scientific information to investors, even if the source material was a conference presentation.
2023-04-27 French
AB Science - Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and summarizes scientific data presented at a professional meeting (American Academy of Neurology 2023 Annual Meeting). It details clinical trial results (Masitinib in ALS), survival analysis, and patient population subsets. This content strongly aligns with an announcement of scientific or clinical findings, which is often released via a press release format to inform investors and the public about key developments. While it contains financial/business information, its primary focus is the scientific update. This type of announcement, summarizing key data points from a conference or study, is best classified as an Earnings Release (ER) if it were quarterly results, but since it is a specific scientific/clinical update announcement, it fits best under the general category of a significant corporate announcement that isn't a formal financial report (like 10-K or IR). Given the options, and recognizing that this is a summary of data presented externally, it functions similarly to an Earnings Release (ER) by announcing key performance/development metrics, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. However, since it is a 'Press Release' summarizing scientific data, and not a formal financial report, it is most closely related to an ER announcing key operational/development milestones, or RNS as a general announcement. Given the context of financial reporting databases, major clinical updates are often grouped with ERs or RNS. Since it is a press release summarizing data, and not a formal regulatory filing like a 10-K or IR, RNS is the most appropriate fallback for a non-standard, yet important, corporate announcement, although ER is also plausible if viewed as a 'results' announcement. I will lean towards RNS as it is a general press release summarizing external presentation data, which is a common use case for RNS when other specific codes don't apply perfectly.
2023-04-27 English
AB Science announces the success of its capital increase by private placement for an amount of 15 million euros
Capital/Financing Update Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces the "SUCCESS OF THE CAPITAL INCREASE BY PRIVATE PLACEMENT FOR AN AMOUNT OF 15 MILLION EUROS". It details the terms of the issuance of new ordinary shares and warrants, the resulting dilution, and the intended use of the funds. This content directly relates to fundraising, financing activities, and changes in capital structure. This aligns perfectly with the definition of 'Capital/Financing Update' (Code: CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it concerns a specific corporate finance event.
2023-04-24 English
AB Science annonce le succès de son augmentation de capital par placement privé pour un montant de 15 millions d’euros
Capital/Financing Update Classification · 1% confidence The document is a press release titled "SUCCES DE L'AUGMENTATION DE CAPITAL PAR PLACEMENT PRIVE POUR UN MONTANT DE 15 MILLIONS D'EUROS" (Success of the Capital Increase by Private Placement for an amount of 15 million Euros). It details the terms, structure, and use of proceeds from a recent equity financing event, including the issuance of new shares (ABSA) and warrants (BSA). This content directly relates to fundraising, financing activities, and capital structure changes. Based on the definitions, the most appropriate code is 'CAP' (Capital/Financing Update). The document is a formal announcement detailing the completion of a capital raise, not a general regulatory filing (RNS) or a report itself (like 10-K or IR).
2023-04-24 French
AB Science annonce la mise en place d’une nouvelle stratégie et le lancement d’une augmentation de capital
Share Issue/Capital Change Classification · 1% confidence The document is a press release ("COMMUNIQUE DE PRESSE") dated April 21, 2023, announcing two major corporate actions: 1) A strategic refocusing on ALS development with Masitinib and the microtubule platform, and 2) The launch of a capital increase via a private placement ("PLACEMENT PRIVE") for a maximum of approximately 15.0 million Euros. The text details the mechanics of the capital increase, including the issuance of new shares (ABSA) with warrants (BSA), pricing, and the intended use of proceeds. It also mentions restructuring of convertible bonds and preference shares. The core subject is fundraising and capital structure change. This aligns directly with the definition for 'Capital/Financing Update' (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple Dividend Notice (DIV). Since it is a detailed announcement of the financing terms, it is classified as CAP rather than a general Regulatory Filing (RNS) or Report Publication Announcement (RPA).
2023-04-21 French
AB Science announces the implementation of a new strategy and the launch of a capital increase
Share Issue/Capital Change Classification · 1% confidence The document is explicitly titled as a "PRESS RELEASE" and announces two main events: a strategic focus update and the "LAUNCH OF A CAPITAL INCREASE VIA A PRIVATE PLACEMENT FOR A MAXIMAL AMOUNT OF EUR 15.0 MILLION". The core of the document details the terms, pricing, and expected proceeds of issuing new ordinary shares with attached warrants. This activity directly relates to fundraising, financing activities, and changes in the capital structure. Therefore, the most appropriate classification is Capital/Financing Update (CAP). It is not an Earnings Release (ER) as it focuses on financing, nor is it a full Annual Report (10-K) or Interim Report (IR).
2023-04-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.